Principal Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $122K | Buy |
24,150
+4,081
| +20% | +$20.7K | ﹤0.01% | 2160 |
|
|
2025
Q1 | $106K | Sell |
20,069
-1,280
| -6% | -$6.77K | ﹤0.01% | 2093 |
|
|
2024
Q4 | $144K | Sell |
21,349
-811
| -4% | -$5.48K | ﹤0.01% | 2129 |
|
|
2024
Q3 | $146K | Sell |
22,160
-13,279
| -37% | -$87.5K | ﹤0.01% | 2128 |
|
|
2024
Q2 | $266K | Sell |
35,439
-362,215
| -91% | -$2.72M | ﹤0.01% | 2081 |
|
|
2024
Q1 | $3.96M | Sell |
397,654
-285,954
| -42% | -$2.85M | ﹤0.01% | 1640 |
|
|
2023
Q4 | $6.74M | Buy |
683,608
+38,133
| +6% | +$376K | ﹤0.01% | 1457 |
|
|
2023
Q3 | $4.94M | Buy |
645,475
+604,618
| +1,480% | +$4.63M | ﹤0.01% | 1541 |
|
|
2023
Q2 | $305K | Buy |
40,857
+1,912
| +5% | +$14.3K | ﹤0.01% | 2076 |
|
|
2023
Q1 | $260K | Buy |
38,945
+4,462
| +13% | +$29.8K | ﹤0.01% | 2121 |
|
|
2022
Q4 | $266K | Buy |
34,483
+1,603
| +5% | +$12.4K | ﹤0.01% | 2137 |
|
|
2022
Q3 | $350K | Buy |
32,880
+6,701
| +26% | +$71.3K | ﹤0.01% | 2038 |
|
|
2022
Q2 | $213K | Sell |
26,179
-9,019
| -26% | -$73.4K | ﹤0.01% | 2285 |
|
|
2022
Q1 | $252K | Sell |
35,198
-273
| -0.8% | -$1.96K | ﹤0.01% | 2284 |
|
|
2021
Q4 | $608K | Buy |
+35,471
| New | +$608K | ﹤0.01% | 2082 |
|